Rigel Pharmaceuticals, Inc.
RIGL
$19.41
$0.130.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 61.37% | 96.58% | 42.32% | 13.29% | -27.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.92% | 96.58% | 42.32% | 13.29% | -27.37% |
| Cost of Revenue | 63.72% | 83.49% | 42.76% | -27.25% | -55.59% |
| Gross Profit | 60.24% | 101.55% | 42.19% | 43.18% | -14.16% |
| SG&A Expenses | 9.94% | 8.80% | 6.62% | 2.60% | -16.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.03% | 26.54% | 13.19% | -5.92% | -29.35% |
| Operating Income | 747.15% | 414.80% | 107.13% | 45.26% | 40.53% |
| Income Before Tax | 1,965.40% | 318.22% | 84.39% | 39.07% | -47.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1,845.86% | 318.22% | 84.39% | 39.07% | -47.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,845.86% | 318.22% | 84.39% | 39.07% | -47.39% |
| EBIT | 747.15% | 414.80% | 107.13% | 45.26% | 40.53% |
| EBITDA | 664.01% | 451.47% | 117.75% | 46.91% | 34.22% |
| EPS Basic | 1,821.28% | 316.14% | 84.56% | 39.65% | -47.84% |
| Normalized Basic EPS | 1,942.05% | 316.23% | 86.59% | 39.64% | 1.15% |
| EPS Diluted | 1,785.11% | 312.12% | 84.56% | 37.50% | -47.84% |
| Normalized Diluted EPS | 1,903.79% | 315.64% | 86.59% | 39.64% | 1.15% |
| Average Basic Shares Outstanding | 1.20% | 0.94% | 1.11% | 0.94% | 0.88% |
| Average Diluted Shares Outstanding | 3.09% | 1.22% | 1.11% | 0.94% | 0.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |